PINK:BSEM
BioStem Technologies, Inc. Stock News
$7.75
-0.335 (-4.15%)
At Close: May 21, 2024
Biostem Technologies, Inc. (BSEM) Q1 2024 Earnings Call Transcript
09:50pm, Tuesday, 14'th May 2024
Biostem Technologies, Inc. (OTCPK:BSEM) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Jeff Ramson - IR, PCG Advisory Group Jason Matuszewski - Chief Executive Officer M
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million
04:01pm, Tuesday, 14'th May 2024
Company Achieves Record-Breaking First Quarter Results for 2024, Marking the Launch of BioStem 2.0 Company Reports First Quarter EBITDA of $4.9 Million Project Continued Growth from Sales of AmnioWrap
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million
04:01pm, Tuesday, 14'th May 2024
- Company Achieves Record-Breaking First Quarter Results for 2024, Marking the Launch of BioStem 2.0 - - Company Reports First Quarter EBITDA of $4.9 Million - - Project Continued Growth from Sales of
BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
08:00am, Tuesday, 07'th May 2024
Conference Call on Tuesday, May 14th, at 4:30 pm ET POMPANO BEACH, FLORIDA, May 7, 2024—BioStem Technologies Inc.
BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
08:00am, Tuesday, 07'th May 2024
POMPANO BEACH, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading biotechnology company focused on the development, manufacture, and commercialization of placental
BioStem Technologies Granted Prioritized Examination for Wound Healing Patent
07:59am, Monday, 06'th May 2024
POMPANO BEACH, FLORIDA, May 6, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts
08:30am, Tuesday, 30'th Apr 2024
POMPANO BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts
08:29am, Tuesday, 30'th Apr 2024
POMPANO BEACH, FLORIDA, April 30, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-deri
BioStem Technologies to Present at the 2024 Planet MicroCap Showcase
07:59am, Thursday, 25'th Apr 2024
BioStem CEO, Jason Matuszewski, will present on Wednesday, May 1, 2024, at 11.30 am PST POMPANO BEACH, FLORIDA, April 25, 2024—BioStem Technologies Inc.
BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior Exchange
08:00am, Wednesday, 24'th Apr 2024
Strategic Audit Completion Set to Enhance BioStem Technologies' Market Position and Shareholder Value POMPANO BEACH, FLORIDA, April 24, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenera
BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior Exchange
08:00am, Wednesday, 24'th Apr 2024
POMPANO BEACH, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference
08:00am, Tuesday, 02'nd Apr 2024
BioStem CEO, Jason Matuszewski, will present on Tuesday, April 9, 2024, at 12:30 pm ET POMPANO BEACH, FLORIDA, April 2, 2024—BioStem Technologies Inc.
Biostem Technologies, Inc. (BSEM) Q4 2023 Earnings Call Transcript
09:17pm, Monday, 01'st Apr 2024
Biostem Technologies, Inc. (BSEM) Q4 2023 Earnings Call Transcript
BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase
04:07pm, Monday, 01'st Apr 2024
-Project Continued Growth from Sales of AmnioWrap2®– –Financial Results Conference Call and Webcast on Monday, April 1, 2024 at 4:30 pm EDT- POMPANO BEACH, FLORIDA, April 1, 2024—BioStem Techn
BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase
04:05pm, Monday, 01'st Apr 2024
-Project Continued Growth from Sales of AmnioWrap2 ® - -Financial Results Conference Call and Webcast on Monday, April 1, 2024 at 4:30 pm EDT- POMPANO BEACH, Fla., April 01, 2024 (GLOBE NEWSWIRE) --